# US 2026/0007622 A1 · Niclosamide formulations and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0007622 A1
- Document ID: US20260007622A1
- Status: Published application
- Kind: A1
- Application number: 19/324,243
- Filed: 2025-09-10
- Published: 2026-01-08
- Earliest claimed: 2020-04-02
- Assignees: The Florida State University Research Foundation, Inc.
- Applicants: Florida State University Research Foundation, Inc.
- Inventors: Eric HOLMES; Gary OSTRANDER
- Web page: https://patentgrep.com/patent/US20260007622A1

## CPC

- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/009: {Sachets, pouches characterised by the material or function of the envelope (with gastric retention A61K9/0065; sachets which are not administered but function merely as a container are classified according to the content, e.g. sachets comprising powder for reconstitution of a drink A61K9/0095)}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/284: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4816: {Wall or shell material}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

## Claims

### Claim 1

A composition of matter, comprising:
(a) composition comprising a niclosamide compound and a permeability enhancer, wherein the permeability enhancer increases the amount of the niclosamide compound capable of being transported across a cell membrane; or
(b) an oral dosage form comprising the composition of (a), wherein the composition comprises a therapeutically effective amount of the niclosamide compound and a permeability-enhancing amount of the permeability enhancer; or
(c) packaged dosage formulation comprising at least one niclosamide compound and at least one permeability enhancer, in a pharmaceutically acceptable dosage in one or more packages, packets, or containers; and instructions for administering the niclosamide compound to treat or prevent human coronavirus infection, wherein the permeability enhancer increases the amount of the niclosamide compound capable of being transported across a cell membrane; or
(d) a kit comprising, in one or more containers, at least one niclosamide compound and at least one permeability enhancer; and instructions for administering the niclosamide compound to treat or prevent human coronavirus infection, wherein the permeability enhancer increases the amount of the niclosamide compound capable of being transported across a cell membrane.

### Claim 2 (depends on 1)

The composition of matter of claim 1, wherein the permeability enhancer of (a)-(d) increases the amount of the niclosamide compound capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer.

### Claim 3 (depends on 2)

The composition of matter of claim 2, wherein the permeability enhancer of (a)-(d) is selected from the group consisting of fatty acids, fatty acid esters, fatty acid salts, glycerol, surfactants, cyclodextrins, sodium salicylate, ethylenediamine tetraacetic acid, citric acid, chitosan, chitosan derivatives, N-trimethyl chitosan chloride, monocarboxymethyl-chitosan, palmitoyl carnitine chloride, acyl carnitines, ethylene glycol tetraacetic acid, 3-alkylamido-2-alkoxypropyl-phosphocholine derivatives, alkanoylcholines, N-acetylated amino acids, mucoadhesive polymers, phospholipids, piperine, 1-methylpiperazine, alpha-amino acids, and mineral oil.

### Claim 4 (depends on 1)

The composition of matter of claim 1, wherein the permeability enhancer of (a)-(d) is selected from the group consisting of one or more fatty acid esters, glycerol, glycerol monocaprylate, and dimethylpalmityl-ammonio propanesulfonate (PPS).

### Claim 5 (depends on 1)

The composition of matter of claim 1, wherein the permeability enhancer of (a)-(d) comprises or consists of glycerol.

### Claim 6 (depends on 1)

The composition of matter of claim 1, wherein the permeability enhancer of (a)-(d) comprises or consists of glycerol monocaprylate and/or dimethylpalmityl-ammonio propanesulfonate (PPS).

### Claim 7 (depends on 1)

The composition of matter of claim 1, wherein the niclosamide compound of (a)-(d) is niclosamide or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The composition of matter of claim 1, wherein the niclosamide compound and the permeability enhancer of (a)-(d) form a mixture that is emulsified.

### Claim 9 (depends on 1)

The composition of matter of claim 1, wherein the composition of (a) and (b) further comprises an enteric- or pH-sensitive coating or layer surrounding the composition.

### Claim 10 (depends on 9)

The composition of matter of claim 9, wherein the composition has an enteric coating surrounding the composition.

### Claim 11 (depends on 10)

The composition of matter of claim 10, wherein the enteric coating comprises one or more enteric polymers selected from among: cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, and polyvinyl acetate phthalate; and anionic polymer based on methacrylic acid and methacrylic acid esters.

### Claim 12 (depends on 1)

The composition of matter of claim 1, wherein the permeability enhancer of (a)-(d) is a cyclodextrin and the niclosamide compound is complexed with the cyclodextrin.

### Claim 13 (depends on 1)

The composition of matter of claim 1, wherein the permeability enhancer of (a) or (b) is present in the composition at a concentration from about 5% to about 95% of the combined weight of the niclosamide compound and the permeability enhancer.

### Claim 14 (depends on 1)

The composition of matter of claim 1, wherein the oral dosage form of (b) is a solid oral dosage form selected from among a table, capsule, sachet, powder, granules, or orally dispersible film; or wherein the oral dosage form of (b) is a liquid oral dosage form or semi-solid selected from among a syrup, solution, ampoule, dispersion, or softgel.

### Claim 15 (depends on 1)

A method for delivering a niclosamide compound to a human or non-human animal subject, comprising administering an effective amount of the composition of (a) or oral dosage form of (b) of claim 1 to the human subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein the composition or oral dosage form is administered to a human subject for treating or preventing human coronavirus infection, or a symptom thereof, in the human subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein the coronavirus is SARS-CoV-2, or a variant thereof.

### Claim 18 (depends on 1)

A method for delivering a niclosamide compound to a human or non-human animal cell, comprising contacting a human or non-human animal cell with the composition of (a) or oral dosage form of (b) of claim 1 in vitro or in vivo.

### Claim 19 (depends on 18)

The method of claim 18, wherein the niclosamide compound is contacted with the cell to inhibit a human coronavirus infection in the cell.

### Claim 20 (depends on 19)

The method of claim 19, wherein the human coronavirus is SARS-CoV-2, or a variant thereof.
